Sökning: WFRF:(Blakeley J.)
> (2022) >
Olaparib maintenanc...
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation : OPINION primary analysis
-
Poveda, A. (författare)
-
- Lheureux, S. (författare)
- Princess Margaret Hospital University of Toronto
-
- Colombo, N. (författare)
- European Institute of Oncology
-
visa fler...
-
- Cibula, D. (författare)
- General University Hospital in Prague
-
- Lindemann, K. (författare)
- Oslo university hospital
-
- Weberpals, J. (författare)
- Ottawa Hospital Research Institute
-
- Bjurberg, M. (författare)
- Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröst/ovarialcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast/ovarian cancer,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Oaknin, A. (författare)
- Vall d’Hebron Institute of Oncology
-
Sikorska, M. (författare)
-
- González-Martín, A. (författare)
- Spanish Center for Biomedical Research Network in Oncology (CIBERONC)
-
- Madry, R. (författare)
- Poznan University of Medical Sciences
-
- Pérez, M. J.Rubio (författare)
- Hospital Universitario Reina Sofia
-
- Ledermann, J. (författare)
- UCL Cancer Institute
-
- Davidson, R. (författare)
- AstraZeneca, UK
-
- Blakeley, C. (författare)
- AstraZeneca, UK
-
- Bennett, J. (författare)
- AstraZeneca, UK
-
- Barnicle, A. (författare)
- AstraZeneca, UK
-
- Škof, E. (författare)
- Institute of Oncology, Ljubljana
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2022
- 2022
- Engelska 7 s.
-
Ingår i: Gynecologic Oncology. - : Elsevier BV. - 0090-8258. ; 164:3, s. 498-504
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
http://www.gynecolog...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: The phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (gBRCAm) who had platinum-sensitive relapsed ovarian cancer (PSROC) and had received ≥2 previous lines of platinum-based chemotherapy. Methods: In this single-arm, open-label, international study, patients who had responded to platinum-based chemotherapy received maintenance olaparib tablets (300 mg twice daily) until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed progression-free survival (PFS) (modified RECIST version 1.1). A key secondary endpoint was PFS by homologous recombination deficiency (HRD) and somatic BRCAm (sBRCAm) status. The primary analysis of PFS was planned for 18 months after the last patient received their first dose. Results: Two hundred and seventy-nine patients were enrolled and received olaparib. At data cutoff (October 2, 2020), 210 PFS events had occurred (75.3% maturity) and median PFS was 9.2 months (95% confidence interval [CI], 7.6–10.9) in the overall population. At 12 and 18 months, 38.5% and 24.3% of patients were progression-free, respectively. In the predefined biomarker subgroups, median PFS was 16.4, 11.1, 9.7, and 7.3 months in sBRCAm, HRD-positive including sBRCAm, HRD-positive excluding sBRCAm, and HRD-negative patients, respectively. The most common treatment-emergent adverse events (TEAEs) were nausea (48.4%) and fatigue/asthenia (44.1%). TEAEs led to dose interruption, dose reduction, and treatment discontinuation in 47.0%, 22.6%, and 7.5% of patients, respectively. Conclusion: Maintenance olaparib demonstrated clinical benefit in patients without a gBRCAm, and across all subgroups, compared with historical placebo controls. There were no new safety signals.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- BRCA
- Maintenance
- Olaparib
- Ovarian cancer
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Poveda, A.
-
Lheureux, S.
-
Colombo, N.
-
Cibula, D.
-
Lindemann, K.
-
Weberpals, J.
-
visa fler...
-
Bjurberg, M.
-
Oaknin, A.
-
Sikorska, M.
-
González-Martín, ...
-
Madry, R.
-
Pérez, M. J.Rubi ...
-
Ledermann, J.
-
Davidson, R.
-
Blakeley, C.
-
Bennett, J.
-
Barnicle, A.
-
Škof, E.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Gynecologic Onco ...
- Av lärosätet
-
Lunds universitet